Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Livionex CVI Topical Treatment
- Development stage
- Phase 1
- Lead developer
- Livionex
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Livionex CVI Topical Treatment is a topical pharmaceutical candidate developed by Livionex for the treatment of chronic venous insufficiency (CVI) and associated conditions, including stasis dermatitis, lower leg edema, and venous ulcers. The formulation utilizes a proprietary technology designed to target and modulate intracellular iron and calcium ions, which are key drivers of inflammation and blood pooling in the lower extremities. By addressing these ionic imbalances, the treatment aims to alleviate the underlying pathophysiology of CVI and promote healing of venous ulcers. It is currently undergoing Phase 1/2 clinical evaluation.
02
Targets
CA2 (Carbonic Anhydrase 2)Fe (Intracellular iron ions)
Beyond the preview
Go deeper on Livionex CVI Topical Treatment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Livionex CVI Topical Treatment.